Steven Arkin, MD, is Executive Director of Pfizer’s Rare Disease and Research Unit. He joined Pfizer in 2005, by way of Wyeth, and has contributed to Pfizer programs in Hemophilia and other Rare Diseases and in Oncology. For hemophilia and other rare diseases, he has led the registration program for Xyntha®, has been the research program lead for PF-05280602, variant of activated coagulation factor VII, and the clinical lead for PF-06252616, an anti-GDF8 drug targeted for Duchenne Muscular Dystrophy. In oncology he has been the clinical lead for the bosutinib programs in autosomal dominant polycystic kidney disease and in Chronic Myeloid Leukemia
Business Development